Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-IIa Trial to Assess the Safety and Antitumor Activity of Autologous CD44v6 CAR T-cells in Acute Myeloid Leukemia and Multiple Myeloma Expressing CD44v6

NCT04097301 is registered in ClinicalTrials.gov with AGC Biologics S.p.A. as lead sponsor.

NCT NCT04097301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04097301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-IIa Trial to Assess the Safety and Antitumor Activity of Autologous CD44v6 CAR T-cells in Acute Myeloid Leukemia and Multiple Myeloma Expressing CD44v6
Lead sponsor
AGC Biologics S.p.A.
Phase
Phase 1/2
Overall status
Terminated
Start date
August 27, 2019
Completion date
June 18, 2021
Enrollment
8 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, multiple myeloma